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Dexmedetomidine is an alpha2 agonist that has been shown to have anxiolytic, analgesic, and
sedative properties making it a popular medication in the intensive care unit. Over the years, its use
has become more widespread. Thus, there have been more adverse events, most notably
hypotension and bradycardia. Over the past few years the side effect of hyperthermia has grown to
recognition with various case reports being documented. We report a case of dexmedetomidine
induced malignant hyperthermia (MH) up to 42.2 degrees Celsius in a patient with underlying
myotonic dystrophy that resolved within 24 hours of discontinuing the medication.The patient is a
40-year-old female with a past medical history of morbid obesity and myotonic dystrophy (DM1)
who presented with shortness of breath. She was found to have pneumonia, fluid overload, and
have a presumed diagnosis of obesity hypoventilation syndrome and COPD. She was treated
conservatively with antibiotics, high-flow nasal cannula oxygen with intermittent noninvasive
ventilation, however, on day 3 she decompensated and was intubated; she was started on fentanyl
and propofol at that time. She slowly improved and on day 4 of intubation dexmedetomidine was
initiated to help titrate off propofol and prepare the patient for extubation. The following day,
approximately 24 hours after initiation of dexmedetomidine, the patient started to develop a fever
that rose to 42.2 degrees celsius. Dexmedetomidine was discontinued. Acetaminophen and
external cooling mechanisms with ice packs and cold intravenous fluids were given, however
despite these interventions she exhibited resistant hyperthermia and was given a dose of
dantrolene and placed on a non-invasive targeted temperature management system, the Arctic Sun,
what is typically used for targeted temperature management post cardiac arrest. The patient
defervesced without recurrence. Fever induced by dexmedetomidine is known as a rare
complication but should be one to be aware of especially with the increased use of this medication.
Given the long list of etiologies for fever in the intensive care unit, usually multiple interventions are
done simultaneously making it difficult to ascertain which intervention helped the most. What makes
this case unique is the fact it took place in a patient with myotonic dystrophy, begging the question if
there is a link between DM1 and MH. The temporal relationship of hyperthermia to initiation of
dexmedetomidine in out patient seemed more than coincidental and had a strong correlation with
the abrupt presence and resolution of hyperthermia in relation to dexmedetomidine.
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